The Conversation (0)
Life Science Big News Roundup: BriaCell Doses First Patient in Phase I/IIa Study; PreveCeutical Receives AU$616,802 R&D Tax Incentive Cash Refund; Lexaria Provides Update on R&D Program with Altria
Oct. 11, 2019 10:00AM PST
Life Science Investing
In case you missed it, here is this week’s life science big news roundup.
In case you missed it, here is this week’s life science big news roundup:
Biotech:
- BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
- PreveCeutical Receives AU$616,802 Research and Development Tax Incentive Cash Refund
- Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria
To see our previous Life Science Investing Big News Roundups, please click here.